AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01170845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sivelestat sodium hydrate
Description: saline or sivelestat sodium hydrate intravenously for 7 days starting the beginning of surgery
Study NCT04130932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomic flooring
Description: Specially designed flooring system to optimize ergonomics of participants
Study NCT00734578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503-AM
Description: SPD503 (Guanfacine Extended Release)-AM Optimized 1-4mg
Study NCT00734578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503-PM
Description: SPD503 (Guanfacine Extended Release)-PM Optimized 1-4mg
Study NCT00734578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to Guanfacine Hydrochloride Extended Release
Study NCT02191670 — intervention group
Intervention type: DRUG
Intervention: METALYSE®
Description: weight-adjusted dosage as single bolus over 5 to 10 seconds
Study NCT01825850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin
Study NCT01825850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Study NCT03328364 — intervention group
Intervention type: DRUG
Intervention: enzalutamide
Description: oral
Study NCT03328364 — intervention group
Intervention type: DRUG
Intervention: docetaxel
Description: intravenous infusion
Study NCT03643224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: A procedure will be performed using a radiofrequency ablation catheter.
Study NCT03703440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active arm
Description: ≥3 group education sessions in addition to usual diabetes care, every 3 months for 12 months
Study NCT03703440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control arm
Description: Usual diabetes care, every 3-month for 12 months
Study NCT01893346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ-AVI
Description: Single IV dose of Ceftazidime and Avibactam. Dosage regimen will vary depending on cohort.
Study NCT02558348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL3818
Description: Administered orally
Study NCT04263324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis/self-care
Description: Learning phase of self-hypnosis/self-care.
Study NCT03016819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL3818
Description: Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
Study NCT03016819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Dacarbazine 1000 mg/m2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle
Study NCT03016819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine 1000 mg/m2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle
Study NCT03016819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL3818 or placebo
Description: AL3818 or placebo 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
Study NCT01869855 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subdural Drainage
Study NCT01869855 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subperiosteal Drainage
Study NCT01509703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High flow therapy
Description: Each patient is treated with nasal high flow at different flow rates (15, 30, 45L/min). The order of flow rates is randomized. Each flow rate will be used for 15 minutes. A wash out time of ten minutes is planned after each phase, during which the patient uses his his individual oxygen flow.
Study NCT03471923 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neurological Examination
Description: The family members and healthy volunteers will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of cervical dystonia and other sensory abnormalities. If the subject is found to have cervical dystonia or any other sensory abnormalities, the subject will be excluded from the study.
Study NCT03471923 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Non-Motor Features
Description: All subjects will be assessed for four non-motor symptoms, including (1) spatial discrimination threshold, (2) temporal discrimination threshold, (3) vibration-induced illusion of movement, and (4) kinesthesia.
Study NCT03701113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk-based protein matrix (MBPM)
Description: Ingestion of the Test Product at 10:00 pm, post-absorptive of the evening meal, each day for the 24 week period of intervention
Study NCT03701113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Habitual dietary behaviour
Description: Subjects to maintain habitual dietary behaviour for the 24 week intervention
Study NCT03705403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darleukin
Description: The product name refers to the molecule structure, in fact, L19-IL2 is a recombinant fusion protein composed of two moieties: L19, a human monoclonal antibody fragment in the single chain Fv (scFv) format, bound via a flexible linker to IL2, the human cytokine Interleukin-2.
Study NCT03705403 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Radiotherapy
Study NCT03705403 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiotherapy
Study NCT02960893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troriluzole
Description: Randomization Phase: Neat (i.e., drug substance without excipients); loose filled capsule.
Study NCT02960893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Randomization Phase: Matching placebo loose filled capsule.
Study NCT02960893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Troriluzole
Description: Extension phase: Neat capsule or formulated capsule (i.e., drug substance with excipients).
Study NCT02960893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troriluzole
Description: Extension phase: Neat capsule or formulated capsule (i.e., drug substance with excipients).
Study NCT03463785 — intervention group
Intervention type: OTHER
Intervention: cone beam computed tomography
Description: The CBCT data sets of both the Chinese and Dutch OSA patients will be obtained using a NewTom 5G CBCT system (QR systems, Verona, Italy), according to the standard imaging protocol. The OSA patients will be treated with mandibular advancement device.
Study NCT04294225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO
Study NCT04294225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT04686552 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cinnamon
Description: 6 g of ground cinnamon
Study NCT01729403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: 150 mcg orally daily, 16 weeks
Study NCT01729403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: patients will continue on their existing dose and regimen of metformin (but not more than the maximum dose specified in the label)
Study NCT01729403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: patients will continue on their existing dose and regimen of metformin (but not more than the maximum dose specified in the label)
Study NCT01729403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally daily, 16 weeks
Study NCT00714896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped-Care
Description: * stage-based expert system written intervention at baseline and 3 months~* in-person stage appropriate counseling at baseline and 3 months~* telephone counseling sessions at weeks 2,4 and 8,~* as-needed brief check-in calls on or 2 days after quit date for those who have set a quit date; and/or check-in calls on days with anticipated high risk situations for former smokers or those who have quit smoking during the study~* optional NRT nicotine replacement therapy in the forms of patch, gum or lozenge for current smokers who are ready to quit smoking and/or for former smokers who report significantly strong smoking urges
Study NCT00714896 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Referral list to smoking cessation classes at Kaiser and the California Smokers Helpline
Study NCT03684967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib treatment: 4mg in the Cycle 1,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days.5mg ,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days
Study NCT01357148 — intervention group
Intervention type: DRUG
Intervention: Sitagliptin Phosphate/Metformin HCl (JANUMET®)
Description: Participants prescribed Sitagliptin Phosphate/Metformin HCl (JANUMET®) in routine clinical practice.
Study NCT01140399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide or Furosemide and Dopamine
Description: Patients randomized to pharmacological treatment receive~* either intravenous diuretics at escalating doses up to 20 mg/h~* or intravenous diuretics up to 20 mg/h and dopamine infusion at a constant rate of 3 mcg/Kg/m.
Study NCT01140399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Description: All loop diuretics will be discontinued. Rate of fluid removal will be based on the extent of fluid overload as assessed by increase in body weight vs the patient's known dry weight~* less than 3 kg 200 ml/h~* more than 3 kg and less than 5 kg 300 mlh~* more than 5 kg 500 mlh~Criteria for achievement of target UF goals are removal of > 50% and \<70% of fluid excess based on the estimated increase in body weight Diuretic infusion is allowed provided that a minimum of 3 hours after the end of the UF session have elapsed, at a maximum cumulative dose of 100 mg furosemide, till start of the next UF session The use of inotropic agents is prohibited
Study NCT02709291 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: behavioral parent training
Description: Parents receive up to 6 sessions of the Family Check-Up program
Study NCT02709291 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: interventionist training
Description: Interventionists are trained in the delivery of the Family Check-Up program and deliver sessions to families in their community
Study NCT02195440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRI-724
Description: 10 - 160 mg/m2, 7 days CIV (in the vein) with 7 days rest per one cycle. Number of Cycles: 6.
Study NCT03806998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketoacids
Description: Provision of 1 Tablet containing 630 mg of ketoacids every 5 kg of body weight during 16 weeks
Study NCT03806998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Provision of placebo capsules similar to active supplement
Study NCT00897104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate (MK0462)
Description: single dose 5 mg rizatriptan p.o.
Study NCT00897104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: sumatriptan
Description: single dose 50 mg sumatriptan p.o.
Study NCT00897104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally
Study NCT03709979 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: C-MAC videolaryngoscope
Description: An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
Study NCT03709979 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC videolaryngoscope
Description: An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
Study NCT03781037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GIVE Module
Description: The GIVE Module is a brief cognitive behavioral intervention targeting youths' beliefs that they are a burden or drain on others. It consists of two sessions embedded within a larger CBT protocol for anxiety or depression.
Study NCT00394524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucommander
Description: Glucommander is a Computer-guided Intravenous (IV) insulin infusion protocol used for glycemic control in inpatients. This algorithm directs the administration of IV insulin in response to Blood Glucose (BG) measurement at the patient's bedside. In this study, the Glucommander program was loaded into a PalmOne (Zire 31, Tungsten E2 by Palm Inc.) handheld personal digital assistant (PDA) device. During the infusion, the nurse entered BG levels into the system and the computer recommended the insulin infusion rate and a variable time to check the next glucose testing. An alarm prompted the scheduled glucose check. The insulin infusion followed the formula: Insulin/Hour = Multiplier × (BG- 60).
Study NCT00394524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard insulin infusion algorithm
Description: Standard insulin infusion Algorithm is a standard paper form insulin infusion algorithm. The algorithm is divided into four columns based on empirically determined insulin sensitivity. The first column was for the most insulin-sensitive patients, and the fourth column was for the most insulin resistant patients. The majority of patients are started in the algorithm 1 column. Insulin resistant patients, such as those receiving glucocorticoids or receiving >80 units of insulin per day as outpatients, started in the algorithm 2 column. The insulin infusion rate was determined by the patient's BG level and was measured hourly until the patient was stable and within the target range. If BG targets were not achieved and the BG had not decreased by at least 60 mg/dL in the preceding hour, the patient was moved to the next column.
Study NCT00525798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMC021 Oral calcitonin
Description: 0.8mg SMC021 - oral calcitonin, once daily
Study NCT00525798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SMC021 Placebo
Description: SMC021 - Placebo, once daily
Study NCT02179424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshop
Description: Intensive psychological intervention included motivation of quitting enhancement, stress management and smoking triggers, craving and relapse are used to provide smoking cessation intervention
Study NCT02179424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face counseling
Description: Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
Study NCT02179424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone counseling
Description: Use motivational interview strategies through phone counseling to provide smoking cessation intervention.
Study NCT02179424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health talk
Description: Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
Study NCT02179424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booklet
Description: A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting.
Study NCT02179424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: Fifteen SMS were sent to subjects included welcome messages, risk of smoking, correction of myths about smoking or quitting, quitting tips, benefits of quitting, encouragement of quitting
Study NCT03926741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSNO
Description: patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
Study NCT03729583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: A 12 week high intensity PR programme was delivered to both groups. The active group had additional breathing control interventions and exercises
Study NCT03729583 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: A 12 week high intensity PR programme was delivered to both groups. The active group had additional breathing control interventions and exercises
Study NCT00883116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Study NCT00883116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Study NCT00883116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT02662491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium
Study NCT02662491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT02662491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Study NCT02662491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03674073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen Vaccines
Description: HCC (3cm≤D ≤5 cm, fewer than three tumors) patients were treated with Microwave Ablation and 7 courses of neoantigen-based DC vaccines.The first neoantigen-based DC vaccine injection will take place up to 30 days following the completion of Microwave Ablation. The day of the first vaccine injection will be referred to as Day 1.The schedule of vaccination is Day 1, Day 8, Day 15, Day 22, Day 50, Day78, Day106.
Study NCT03674073 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave Ablation
Description: ALL the HCC patients will be treated by Microwave Ablation.
Study NCT03674073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation
Description: ALL the HCC patients will be treated by Microwave Ablation.
Study NCT04500002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isonicotinic Acid Hydrazide
Description: total dose 900 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
Study NCT04500002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprosrol 800mcg will be given to all patients for induction of abortion
Study NCT04500002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprosrol 800mcg will be given to all patients for induction of abortion
Study NCT01357538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posiformin 2 %, bibrocathol
Description: A strip of 5 mm eye ointment applied 3 times per day to the eye lid
Study NCT01357538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: corresponding vehicle, eye ointment applied to the eye lid
Study NCT03352622 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CASES
Description: Patients with RA with methotrexate therapy and inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; That present problems of effectiveness.
Study NCT01291810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNF Kinoid
Description: TNF Kinoid
Study NCT01291810 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: WFI
Description: WFI
Study NCT03352622 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROLS
Description: Patients with RA with methotrexate therapy inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; No problems of effectiveness
Study NCT03592108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSR remote monitoring
Description: The intervention will consist to modify the method used to analyse the data collected by remote monitoring in OSA-patients treated by CPAP (device : AirSense™10 Autoset™, ResMed) in order to alert physicians when Cheynes-Stokes respiration (CSR) occurs during sleep and then to set up emergency pulmonology and cardiology consultations to screen the onset of a significant cardiac event (heart failure, rhythm disorder, diastolic dysfunction).
Study NCT04008615 — intervention group
Intervention type: OTHER
Intervention: 2 times : 6-minute stepper test with cardiorespiratory parameters and gaz exchange monitoring (with a rest of 20min between each test).
Description: For the 6-minute stepper test, please refer to NCT02842463 and NCT04004689. Gaz exchange analyzer will be calibrate before every test. Data will be recorded breath by breath.~Heart rate will be monitored using a 12-lead electrocardiogram. Transcutaneous oxygen saturation will be assessed using a pulse oxymetry system at the earlobe.
Study NCT01554553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior crural repair
Description: All patients receive gastrectomy, however patients randomized to the experimental arm will also receive posterior crural repair to determine if this will reduce GERD post sleeve gastrectomy.